title: Synthetic modification of prostaglandin f(2alpha) indicates different structural determinants for binding to the prostaglandin F receptor versus the prostaglandin transporter.
abstract: Several principles governing the binding of E series prostaglandins to EP receptors have emerged in recent years. The C-1 carboxyl group binds electrostatically to a conserved arginine residue in the seventh transmembrane segment of the receptor. Prostaglandin E analogs involving bioisosteric replacements of the carboxyl group, such as acylsulfonamide, are also active. In addition, structurally similar esters may also exhibit similar affinity, presumably by virtue of hydrogen bonding. Other regions of the substrate molecule appear to bind to other domains of EP receptors, either via hydrophobic interactions or by hydrogen bonding. Less information is available about the structural requirements for substrate binding to FP receptors. Prostanoids also bind to the prostaglandin transporter PGT. In this case, a conserved C-1 carboxyl group is critically important, since C-1 esters exhibit little affinity. Here we examined the binding of chemically diverse PGF(2alpha) structural analogs to the FP receptor and compared these with binding by the PG transporter. PGT recognized a wide range of anionic substituents. In contrast, the carboxylic acid group was essential for optimal binding to the FP receptor, since replacement by larger moieties with a similar pK(a), such as acylsulfonamide and tetrazole, substantially decreased binding affinity. Interestingly, insertion of cyclic substituents in the omega chain increased binding to the FP receptor but reduced affinity for PGT, and substitution for the 15-hydroxyl group produced only a modest reduction in FP receptor binding, but eliminated binding by PGT. Because extracellular PGF(2alpha) may compete for binding between FP receptors and PGT, these findings have implications for designing PGF(2alpha) analogs for treating disease states.
authors.affiliation: Department of Medicine, Physiology, and Biophysics, Albert Einstein College of Medicine, Bronx, New York, USA. schuster@aecom.yu.edu
authors.forename: V L
authors.initials: VL
authors.lastname: Schuster
authors.forename: S
authors.initials: S
authors.lastname: Itoh
authors.forename: S W
authors.initials: SW
authors.lastname: Andrews
authors.forename: R M
authors.initials: RM
authors.lastname: Burk
authors.forename: J
authors.initials: J
authors.lastname: Chen
authors.forename: K M
authors.initials: KM
authors.lastname: Kedzie
authors.forename: D W
authors.initials: DW
authors.lastname: Gil
authors.forename: D F
authors.initials: DF
authors.lastname: Woodward
mesh_terms: D000818:Animals; D017920:Antiporters / Q000737:chemistry / Q000378:metabolism*; D019556:COS Cells; D004268:DNA-Binding Proteins / Q000737:chemistry / Q000378:metabolism*; D015237:Dinoprost / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism*; D006367:HeLa Cells; D006801:Humans; D008968:Molecular Conformation; D027361:Organic Anion Transporters; D011485:Protein Binding; D011982:Receptors, Prostaglandin / Q000737:chemistry / Q000378:metabolism*; D013329:Structure-Activity Relationship
chemical_list: D017920:Antiporters; D004268:DNA-Binding Proteins; D027361:Organic Anion Transporters; D011982:Receptors, Prostaglandin; C503526:SLCO2A1 protein, human; C034671:prostaglandin F2alpha receptor; D015237:Dinoprost